SCHEMBL30153378

SCHEMBL30153378

CCc1ccc(-c2nc(-c3cccc(C(=O)O)c3)no2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.63
RAB9A P51151 5/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
NR1H4 Q96RI1 3/20 0.57
MAOA P21397 1/20 0.57
BLVRB P30043 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
TP53 P04637 3/20 0.56
MAPT P10636 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
BCL2 P10415 1/20 0.48
CASP3 P42574 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
DHFR P00374 1/20 0.47
S1PR1 P21453 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL60690 1.00 NPC1 (0.63) NPC1RAB9AL3MBTL1NR1H4MAOA
SCHEMBL59529 0.87 NPC1 (0.67) NPC1RAB9AL3MBTL1NR1H4MAOA
SCHEMBL60775 0.86 NPC1 (0.59) NPC1RAB9AL3MBTL1NR1H4MAOA
SCHEMBL59247 0.86 RAB9A (0.72) NPC1RAB9AL3MBTL1NR1H4MAOA
SCHEMBL60427 0.86 NPC1 (0.76) NPC1RAB9AL3MBTL1NR1H4MAOA
SCHEMBL59426 0.85 NPC1 (0.67) NPC1RAB9AL3MBTL1NR1H4MAOA
SCHEMBL17336565 0.84 NPC1 (0.72) NPC1RAB9AL3MBTL1NR1H4MAOA
SCHEMBL60333 0.83 MAOA (0.68) NPC1RAB9AL3MBTL1NR1H4MAOA
SCHEMBL5345798 0.83 NPC1 (0.80) NPC1RAB9AL3MBTL1NR1H4MAOA
SCHEMBL60606 0.83 NPC1 (0.67) NPC1RAB9AL3MBTL1NR1H4MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4101846-A1 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE PTC Therapeutics, Inc. (US) 2022-12-14 EP disclosed